KR20230100953A - Composition For Improving Hypersensitive Immune Response - Google Patents
Composition For Improving Hypersensitive Immune Response Download PDFInfo
- Publication number
- KR20230100953A KR20230100953A KR1020210190651A KR20210190651A KR20230100953A KR 20230100953 A KR20230100953 A KR 20230100953A KR 1020210190651 A KR1020210190651 A KR 1020210190651A KR 20210190651 A KR20210190651 A KR 20210190651A KR 20230100953 A KR20230100953 A KR 20230100953A
- Authority
- KR
- South Korea
- Prior art keywords
- immune response
- ethyl acetate
- composition
- cells
- hypersensitivity
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000028993 immune response Effects 0.000 title claims abstract description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 69
- 241000208340 Araliaceae Species 0.000 claims abstract description 68
- 235000008434 ginseng Nutrition 0.000 claims abstract description 68
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 67
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 67
- 239000000284 extract Substances 0.000 claims abstract description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000002038 ethyl acetate fraction Substances 0.000 claims abstract description 30
- 208000026935 allergic disease Diseases 0.000 claims abstract description 28
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002537 cosmetic Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- 206010058141 Skin graft rejection Diseases 0.000 claims description 6
- 208000010247 contact dermatitis Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 5
- 244000105624 Arachis hypogaea Species 0.000 claims description 4
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 4
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 201000010435 allergic urticaria Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 235000020232 peanut Nutrition 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 235000014102 seafood Nutrition 0.000 claims description 4
- 229960001005 tuberculin Drugs 0.000 claims description 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 4
- 201000005354 penicillin allergy Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract description 12
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 abstract description 9
- 238000005194 fractionation Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 31
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000036039 immunity Effects 0.000 description 14
- 210000001165 lymph node Anatomy 0.000 description 14
- 108090000176 Interleukin-13 Proteins 0.000 description 13
- 239000012264 purified product Substances 0.000 description 13
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- -1 pack Substances 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 239000000344 soap Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000004073 interleukin-2 production Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000018711 interleukin-13 production Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101001076402 Mus musculus Interleukin-13 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 210000000940 dendritic epidermal T lymphocyte Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010040400 serum sickness Diseases 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000123966 Blomia tropicalis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- GTRGJZLUTFVHOT-UHFFFAOYSA-N butane-1,4-diol;ethyl acetate Chemical compound CCOC(C)=O.OCCCCO GTRGJZLUTFVHOT-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 상기 에틸아세테이트 분획물을 제거하여 수득된 분획 정제물을 포함하는, 과민성 면역 반응의 개선용 조성물을 제공한다. 본 발명의 인삼잎 추출물에 에틸아세테이트와 물을 첨가하여 분획한 후 상기 에틸아세테이트 분획물을 제거하여 수득된 분획 정제물은 알파-베타 T 세포에는 영향을 미치지 않으면서 감마-델타 T 세포의 활성을 특이적으로 억제함으로써 과민성 면역 반응을 개선하고, 과민성 면역 반응에 의해 유발되는 질환을 예방 또는 치료하는 효과가 있다.The present invention provides a composition for improving hypersensitivity immune response comprising a purified fraction obtained by adding ethyl acetate and water to a ginseng leaf extract and removing the ethyl acetate fraction. After fractionation by adding ethyl acetate and water to the ginseng leaf extract of the present invention, the purified fraction obtained by removing the ethyl acetate fraction specifically showed activity of gamma-delta T cells without affecting alpha-beta T cells. By suppressing the immune response, it is effective in improving the hypersensitive immune response and preventing or treating diseases caused by the hypersensitive immune response.
Description
본 발명은 과민성 면역 반응의 개선용 조성물, 또는 과민성 면역 반응에 의해 유발되는 질환의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for improving an overactive immune response or a composition for preventing or treating diseases caused by an overactive immune response.
면역은 신체가 자기(self)와 비-자기(non-self)를 구별하여 외부로부터 침입하는 미생물, 세균, 바이러스뿐만 아니라 체내 조직이나 불필요한 산물 등을 비-자기 항원으로 인식하여 특이적으로 반응하여 항체를 생산하고 이를 제거함으로서 생체의 항상성을 유지하는 현장이며 체내에 존재하는 자기 방어체계이다(비특허문헌 1). 이 방어체계에는 항원에 대한 특이성에 따라 선천 면역(Innate immunity, non-specific immunity)과 후천 면역(adaptive immunity, specific immunity)으로 구분된다.Immunity is when the body differentiates between self and non-self, recognizes not only microorganisms, bacteria, and viruses invading from the outside, but also body tissues and unnecessary products as non-self antigens, and responds specifically to them. It is a field that maintains the homeostasis of the body by producing and removing antibodies and is a self-defense system present in the body (Non-Patent Document 1). This defense system is divided into innate immunity (non-specific immunity) and adaptive immunity (specific immunity) according to the specificity for the antigen.
먼저, 선천 면역은 피부나 점막과 같은 물리적 방어막 이외에도 대식세포(Macrophage)와 자연 살해 세포(Natural killer, NK 세포) 등의 면역세포들이 관여한다. 두 번째로 후천 면역은 선천 면역계의 방어막을 통과한 항원들에 특이적으로 작용하는 면역체계로 이는 다시 체액성 면역(Humoral immunity)과 세포성 면역(Cellular immunity)으로 분류된다. 체액성 면역은 B-세포의 항체에 의한 혈액에서의 반응이고 세포성 면역은 T-세포가 활성화하거나 대식세포를 유인하여 다양한 종류의 사이토카인(Cytokine)과 긴밀한 상호 작용에 의하여 제어가 이루어진다.First, innate immunity involves immune cells such as macrophages and natural killer cells (NK cells) in addition to physical defenses such as skin or mucous membranes. Second, acquired immunity is an immune system that acts specifically on antigens that have passed through the defenses of the innate immune system, which is further classified into humoral immunity and cellular immunity. Humoral immunity is a response in blood by B-cell antibodies, and cellular immunity is controlled by T-cell activation or macrophage attraction and close interaction with various types of cytokines.
세포성 면역에 관여하는 T-세포는 다양한 아형(subset)으로 구성되어 있는데, 이 중에서 γδ-T 세포(이하, 감마-델타 T 세포라고 함)는 인간의 피부나 폐, 장과 같이 병원균과의 접촉이 빈번한 점막 등에 주로 존재하는 선천성 T 세포로서 스트레스 받은 세포를 초기에 제거하거나 박테리아 등의 감염시 중요한 세포로서 알려져 있다.T-cells involved in cellular immunity are composed of various subtypes (subset), among which γδ-T cells (hereinafter referred to as gamma-delta T cells) are resistant to pathogens such as human skin, lungs, and intestines. A congenital condition that mainly exists in mucous membranes that are in frequent contact As a T cell, it is known as an important cell that eliminates stressed cells at an early stage or when infected with bacteria.
이러한 감마-델타 T 세포는 αβ-T 세포(이하, 알파-베타 T 세포라고 함)가 관여하는 전신 면역력과는 다른 생리학적 메커니즘을 보인다. 표피에 상재하는 감마-델타 T 세포는 림프절 또는 말초혈액과 같은 조직에 주로 존재하는 알파-베타 T 세포와 달리 다수의 덴드라이트(dendrite)를 가진 특징적인 형태를 이루며 주변의 케라티노사이트(keratinocyte), 멜라노사이트(melanocyte), 랑게르한스(Langerhans) 세포 등의 표피 구성세포들과 긴밀하게 연결되어 있다. 이러한 특성으로 인하여 감마-델타 T 세포는 수지상 표피 T 세포(dendritic epidermal T cells, DETC)라고도 불린다. 또한 감마-델타 T 세포는 주변의 세포와 직접적인 접촉에 의해 상호작용을 수행할 뿐 아니라, 직접 접촉하고 있지 않은 다른 피부 내 면역세포 또는 케라티노사이트, 멜라노사이트, 섬유아세포 등과도 모종의 수단에 의하여 상호작용을 수행하는 것으로 알려져 있다.These gamma-delta T cells exhibit physiological mechanisms different from systemic immunity involving αβ-T cells (hereinafter referred to as alpha-beta T cells). Gamma-delta T cells residing in the epidermis, unlike alpha-beta T cells, which are mainly present in tissues such as lymph nodes or peripheral blood, form a characteristic shape with multiple dendrites and form a number of dendrites. , melanocytes, Langerhans cells, and other epidermal constituent cells. Due to these characteristics, gamma-delta T cells are also called dendritic epidermal T cells (DETC). In addition, gamma-delta T cells not only interact with neighboring cells by direct contact, but also interact with other immune cells in the skin or keratinocytes, melanocytes, and fibroblasts that are not in direct contact by some means. known to interact.
기존의 면역 연구는 대부분 알파-베타 T 세포로 이루어졌으나, 최근에는 감마-델타 T 세포를 이용한 연구가 활발히 이루어지고 있다. 예를 들면, 피부 과민성 면역 반응으로 인한 질병 등의 치료 목적을 위한 약물의 개발에서 전신 면역에 관여되는 알파-베타 T 세포에는 영향을 미치지 않으면서 상피 세포의 면역에 영향을 주는 감마-델타 T 세포의 비정상적인 활성을 특이적으로 억제하는 성분을 찾아 우리 몸의 면역체계에 대한 부작용을 최소화하면서 피부 또는 호흡기 관련 질병의 치료 또는 개선을 달성하려는 연구가 진행되고 있다(비특허문헌 2, 3).Most of the existing immune studies have been conducted with alpha-beta T cells, but recently, studies using gamma-delta T cells have been actively conducted. For example, in the development of drugs for the treatment of diseases caused by skin hypersensitivity immune response, gamma-delta T cells that affect epithelial immunity without affecting alpha-beta T cells involved in systemic immunity. Research is being conducted to find a component that specifically inhibits the abnormal activity of , and to achieve treatment or improvement of skin or respiratory diseases while minimizing side effects on the body's immune system (Non-Patent
과민성 면역 반응에 의해 유발되는 질환은 1형 내지 4형으로 구분되는데, 1형은 즉각적 과민 반응에 의한 것으로, 아토피성 피부염, 알레르기성 두드러기, 알레르기성 비염, 알레르기성 천식, 아낙팔락시스, 식품(우유, 계란, 땅콩, 콩, 밀, 해산물 등)에 의한 알레르기, 페니실린 알레르기 등이 1형으로 분류된다. 2형은 항체매개 과민 반응에 의한 것으로, 자가면역 용혈성 빈혈, 굿파스처 증후군 등이 이에 속하고, 3형은 면역복합체매개 과민 반응에 의한 것으로, 전신 홍반 루푸스, 혈청병, 아르투스 반응 등이 해당된다. 4형은 세포매개 과민 반응에 의한 것으로, 민감화된 T 세포 또는 T 세포에서 유래된 사이토카인에 의해서 조직 손상이 유발된다. 통상적으로, 접촉성 피부염, 접촉성 아토피 피부염, 피부이식 거부반응, 자가면역성 심근염, 인슐린 의존형 당뇨병, 염증성 결절, 말초신경병증, 하시모토병, 염증성 장질환, 다발성경화증, 류마티스 관절염, 투베르쿨린 반응 등이 4형으로 분류된다. Diseases caused by hypersensitivity immune reactions are classified into
인삼(Panax ginseng)은 식물 분류학상으로 오갈피나무과(Araliaceae)의 인삼속(Panax)에 속하는 다년생 음지성 초본식물로서 인삼의 뿌리는 오래 전부터 한방에서 중요한 약재로 사용되었다. Ginseng ( Panax ginseng ) is a perennial shade-resistant herbaceous plant belonging to the genus Panax of Araliaceae in terms of plant taxonomy, and the root of ginseng has long been used as an important medicinal material in oriental medicine.
인삼 지상부는 인삼을 수확하고 남은 부산물로 취급되었으나, 최근에는 이를 활용하기 위한 다양한 방법이 연구되고 있다. 특히 인삼잎의 경우, 지리적 환경 또는 계절에 따라 차이는 있으나, 진세노사이드 Re, Rd, Rb2의 함유량이 높은 것으로 알려져 있다. 인삼잎을 다양한 용매로 추출하고 분획함으로써 원하는 유효성분을 고농도로 함유한 인삼잎 추출물을 이용한 각종 조성물에 대한 연구가 지속적으로 이루어지고 있다(특허문헌 1). The above-ground part of ginseng has been treated as a by-product left after harvesting ginseng, but recently, various methods for utilizing it are being studied. In particular, in the case of ginseng leaves, although there is a difference depending on the geographical environment or season, it is known that the content of ginsenosides Re, Rd, Rb 2 is high. By extracting and fractionating ginseng leaves with various solvents, research on various compositions using ginseng leaf extracts containing high concentrations of desired active ingredients has been continuously conducted (Patent Document 1).
본 발명자들은 과민성 면역 반응을 효과적으로 조절할 수 있는 천연 성분에 대한 연구를 계속하던 중에 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 에틸아세테이트 분획물을 제거하여 수득된 분획 정제물이, 알파-베타 T 세포에는 영향을 미치지 않으면서 감마-델타 T 세포의 활성을 특이적으로 억제하는 효과가 있어서 과민성 면역 반응의 개선을 위한 유효성분으로 활용할 수 있음을 확인하고 본 발명을 완성하였다.The inventors of hypersensitivity immunity While continuing research on natural ingredients that can effectively control the reaction, the purified fraction obtained by adding ethyl acetate and water to ginseng leaf extract and removing the ethyl acetate fraction was found to have no effect on alpha-beta T cells. The present invention was completed after confirming that it has an effect of specifically inhibiting the activity of gamma-delta T cells and thus can be used as an active ingredient for improving hypersensitive immune response.
본 발명은 과민성 면역 반응을 개선하는 효과가 있는 천연 성분을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a natural ingredient having an effect of improving an overactive immune response.
본 발명의 일 양태는 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 상기 에틸아세테이트 분획물을 제거하여 수득된 분획 정제물을 포함하는, 과민성 면역 반응의 개선용 조성물을 제공한다. One aspect of the present invention provides a composition for improving hypersensitivity immune response comprising a purified fraction obtained by adding ethyl acetate and water to a ginseng leaf extract and removing the ethyl acetate fraction.
본 발명의 다른 양태는 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 상기 에틸아세테이트 분획물을 제거하여 수득된 분획 정제물을 포함하는, 과민성 면역 반응 반응에 의해 유발되는 질환의 예방 또는 치료용 조성물을 제공한다. Another aspect of the present invention provides a composition for preventing or treating diseases caused by hypersensitivity immune response, comprising a purified fraction obtained by adding ethyl acetate and water to a ginseng leaf extract and removing the ethyl acetate fraction. do.
본 발명의 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 에틸아세테이트 분획을 제거하여 수득된 분획 정제물은 알파-베타 T 세포에는 영향을 미치지 않으면서 감마-델타 T 세포의 활성을 특이적으로 억제함으로써 과민성 면역 반응을 개선하고, 과민성 면역 반응에 의해 유발되는 질환을 예방 또는 치료하는 효과가 있다. The purified fraction obtained by adding ethyl acetate and water to the ginseng leaf extract of the present invention and removing the ethyl acetate fraction specifically inhibits the activity of gamma-delta T cells without affecting alpha-beta T cells. It has the effect of improving hypersensitivity immune response and preventing or treating diseases caused by hypersensitivity immune response.
도 1은 제조예 1-1의 인삼잎 물 추출물에 대해 림프절 T 세포의 생존율(a), 상피 T 세포의 생존율(b), IL-2 생산율(c) 및 IL-13 생산율(d)을 측정한 결과이다.
도 2는 제조예 1-2의 인삼잎 에탄올 추출물에 대해 림프절 T 세포의 생존율(a), 상피 T 세포의 생존율(b), IL-2 생산율(c) 및 IL-13 생산율(d)을 측정한 결과이다.
도 3은 제조예 1-3의 인삼잎 에탄올 추출물의 에틸아세테이트 분획 정제물에 대해 림프절 T 세포의 생존율(a), 상피 T 세포의 생존율(b), IL-2 생산율(c) 및 IL-13 생산율(d)을 측정한 결과이다.
도 4는 제조예 1-4의 인삼잎 에탄올 추출물의 에틸아세테이트 분획물에 대해 림프절 T 세포의 생존율(a), 상피 T 세포의 생존율(b), IL-2 생산율(c) 및 IL-13 생산율(d)을 측정한 결과이다.1 is a measurement of lymph node T cell viability (a), epithelial T cell viability (b), IL-2 production rate (c) and IL-13 production rate (d) for the water extract of ginseng leaves of Preparation Example 1-1. is a result
Figure 2 measures the survival rate of lymph node T cells (a), the survival rate of epithelial T cells (b), the production rate of IL-2 (c) and the production rate of IL-13 (d) for the ethanol extract of ginseng leaves of Preparation Example 1-2 is a result
Figure 3 shows the survival rate of lymph node T cells (a), epithelial T cell survival rate (b), IL-2 production rate (c) and IL-13 for the ethyl acetate fraction purified product of the ethanol extract of ginseng leaf of Preparation Example 1-3 This is the result of measuring the production rate (d).
Figure 4 shows the survival rate of lymph node T cells (a), epithelial T cell survival rate (b), IL-2 production rate (c) and IL-13 production rate ( d) is the result of measuring.
이하, 본 발명에 대한 이해를 돕기 위해 본 발명을 더욱 상세하게 설명한다. 이때, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Hereinafter, the present invention will be described in more detail to aid understanding of the present invention. At this time, the terms or words used in this specification and claims should not be construed as being limited to ordinary or dictionary meanings, and the inventor appropriately defines the concept of terms in order to explain his/her invention in the best way. It should be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle that it can be done.
본 발명의 일 양태는 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 상기 에틸아세테이트 분획물을 제거하여 수득된 분획물을 포함하는, 과민성 면역 반응의 개선용 조성물을 제공한다. One aspect of the present invention provides a composition for improving hypersensitivity immune response comprising a fraction obtained by adding ethyl acetate and water to a ginseng leaf extract and removing the ethyl acetate fraction.
본 발명에서 인삼잎 추출물은 원료 또는 이의 건조물로부터 추출하여 얻을 수 있으며, 상기 추출물의 원료는 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 원료는 인삼 새싹, 인삼잎 또는 인삼 줄기로 이루어진 군으로부터 선택되는 어느 하나일 수 있고, 바람직하게는 인삼 새싹 또는 인삼잎이 이용될 수 있으며, 더 바람직하게는 인삼잎이 이용될 수 있다.In the present invention, the ginseng leaf extract can be obtained by extracting from a raw material or a dried product thereof, and the raw material of the extract can be used without limitation, such as cultivated or commercially available. The raw material may be any one selected from the group consisting of ginseng sprouts, ginseng leaves, and ginseng stems, preferably ginseng sprouts or ginseng leaves, and more preferably ginseng leaves.
본 발명에서 추출물은 원료로부터 임의의 방법으로 추출된 물질을 의미하며, 이렇게 추출된 추출액, 이로부터 얻을 수 있는 농축액, 상기 농축액의 건조물 및 분말을 제한 없이 모두 포함하는 의미로 사용된다.In the present invention, the extract refers to a material extracted from a raw material by any method, and is used in the sense of including all of the extracted extract, the concentrate obtained therefrom, and the dried product and powder of the concentrate without limitation.
상기 추출물을 원료로부터 추출하여 수득할 때, 추출 방법으로는 용매 추출법, 초음파 추출법, 여과법 및 환류 추출법 등 종래 알려진 통상적인 추출 방법을 모두 사용할 수 있으며, 바람직하게는 용매 추출법이나 환류 추출법을 이용함으로써 제조할 수 있다. 상기 추출 과정은 수회 반복할 수 있으며, 이후에 농축, 분무건조, 동결건조 등의 단계를 추가적으로 거칠 수 있다. 구체적으로, 수득한 추출물을 감압 농축하여 농축액을 얻고, 상기 농축액을 열풍으로 건조하거나, 동결건조시킨 후 분쇄기를 이용하여 고농도의 추출 분말을 제조할 수 있다. 추출물은 추출물을 추가적으로 분획하여 얻은 분획물 또는 정제물도 포함한다.When the extract is obtained by extraction from a raw material, all known conventional extraction methods such as solvent extraction, ultrasonic extraction, filtration and reflux extraction may be used as extraction methods, preferably prepared by using solvent extraction or reflux extraction. can do. The extraction process may be repeated several times, and then additional steps such as concentration, spray drying, and lyophilization may be performed. Specifically, the obtained extract may be concentrated under reduced pressure to obtain a concentrate, and the concentrate may be dried with hot air or freeze-dried, and then a high-concentration extract powder may be prepared using a grinder. The extract also includes fractions or purified products obtained by further fractionating the extract.
상기 추출물은 물, 유기용매, 초임계 유체 및 이들의 혼합물로 이루어진 군으로부터 선택되는 1종 이상을 추출용매로 사용할 수 있다. 상기 유기용매는 알코올, 바람직하게는 C1-C4의 저급 알코올, 헥산(n-헥산), 에테르, 글리세롤, 프로필렌글리콜, 부틸렌글리콜, 에틸아세테이트, 메틸아세테이트, 디클로로메탄, 클로로포름, 에틸아세테이트, 벤젠 및 이들의 혼합용매로 이루어지는 군으로부터 선택되는 어느 하나일 수 있고, 바람직하게는 에탄올이다.The extract may use at least one selected from the group consisting of water, organic solvents, supercritical fluids, and mixtures thereof as an extraction solvent. The organic solvent is an alcohol, preferably a C 1 -C 4 lower alcohol, hexane (n-hexane), ether, glycerol, propylene glycol, butylene glycol, ethyl acetate, methyl acetate, dichloromethane, chloroform, ethyl acetate, It may be any one selected from the group consisting of benzene and mixed solvents thereof, preferably ethanol.
상기 추출물 제조시, 추출은 5℃ 내지 90℃, 또는 10℃ 내지 80℃에서 실시될 수 있고, 바람직하게는 15℃ 내지 70℃에서 실시될 수 있으며, 더욱 바람직하게는 17℃ 내지 50℃에서 실시될 수 있으나, 이에 한정되지 아니한다. 추출은 2시간 내지 12시간 동안 실시될 수 있고, 바람직하게는 5시간 내지 10시간 동안 실시될 수 있으며, 더욱 바람직하게는 6시간 내지 8시간 동안 실시될 수 있다. 추출은 1회 내지 7회 실시될 수 있고, 바람직하게는 1회 내지 4회 실시될 수 있으며, 더욱 바람직하게는 1회 내지 2회 실시될 수 있으나, 이에 한정하지 않는다.When preparing the extract, the extraction may be carried out at 5 ° C to 90 ° C, or 10 ° C to 80 ° C, preferably at 15 ° C to 70 ° C, more preferably at 17 ° C to 50 ° C. It can be, but is not limited to. Extraction may be performed for 2 to 12 hours, preferably for 5 to 10 hours, and more preferably for 6 to 8 hours. Extraction may be performed 1 to 7 times, preferably 1 to 4 times, and more preferably 1 to 2 times, but is not limited thereto.
본 발명에서 인삼잎 추출물의 정제 방법은 인삼잎 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시키는 방법, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등으로 추가적으로 실시되는 다양한 정제 방법을 포함한다. 이와 같은 정제 공정에 의해 과민성 면역 반응의 개선 효능이 우수한 성분을 강화시킬 수 있다. In the present invention, the purification method of the ginseng leaf extract is a method of passing the ginseng leaf extract through an ultrafiltration membrane having a certain molecular weight cut-off value, various chromatography (made for separation according to size, charge, hydrophobicity or affinity) It includes various purification methods additionally carried out such as separation by By such a purification process, it is possible to enhance a component having an excellent effect on improving hypersensitivity immune response.
상기 크로마토그래피는 예를 들어 컬럼 크로마토그래피, 고성능액체 크로마토그래피(HPLC), 이온교환 크로마토그래피, 친화성 크로마토그래피 및 크기배제 크로마토그래피로 이루어진 군으로부터 선택되는 1종 이상일 수 있다.The chromatography may be, for example, at least one selected from the group consisting of column chromatography, high performance liquid chromatography (HPLC), ion exchange chromatography, affinity chromatography, and size exclusion chromatography.
본 발명에서는 과민성 면역 반응의 개선 효능이 우수한 성분이 고농도로 포함되도록 정제하기 위해, 상기 인삼잎 추출물에 물과 에틸아세테이트를 첨가하여 분획한 후 상기 에틸아세테이트 분획물을 제거함으로써 인삼잎 추출물의 분획 정제물을 수득할 수 있다.In the present invention, in order to purify components having excellent efficacy in improving hypersensitivity immune response at high concentration, fractionation is performed by adding water and ethyl acetate to the ginseng leaf extract, and then the ethyl acetate fraction is removed to obtain a fractionated purified product of the ginseng leaf extract. can be obtained.
또한, 상기 인삼잎 추출물 대 여기에 첨가되는 물은 부피비로 1:2 내지 1:20, 또는 1:2.5 내지 1:15, 또는 1:3 내지 1:12, 또는 1:7 내지 1:10으로 첨가될 수 있다. In addition, the volume ratio of the ginseng leaf extract to the water added therein is 1:2 to 1:20, or 1:2.5 to 1:15, or 1:3 to 1:12, or 1:7 to 1:10. may be added.
본 발명은 이와 같이 인삼잎 추출물에 대해 에틸아세테이트를 이용한 분획을 수행하고 에틸아세테이트 분획물을 제거하여 에틸아세테이트에 용해되는 성분을 제거한 분획 정제물의 경우, 전신 면역에 관여하는 알파-베타 T 세포의 활성에는 영향을 미치지 않으면서 상피 세포의 면역에 영향을 주는 감마-델타 T 세포의 활성만 특이적으로 억제하는 효과가 있다. 이에 따라, 본 발명의 인삼잎 추출물에 대해 에틸아세테이트를 이용한 분획을 수행하고 에틸아세테이트 분획물을 제거하여 에틸아세테이트에 용해되는 성분을 제거한 분획 정제물을 이용하면, 전신 면역에 관여하는 인자인 IL-2에는 변화가 없으면서 과민성 면역 반응의 지표인 IL-13만 감소되므로, 신체의 방어기작은 유지시키면서 과민성 면역 반응을 개선하는 효과가 있음을 확인할 수 있다. In the case of the fraction-purified product obtained by performing fractionation using ethyl acetate on the ginseng leaf extract and removing components soluble in ethyl acetate by removing the ethyl acetate fraction, the activity of alpha-beta T cells involved in systemic immunity is It has the effect of specifically suppressing only the activity of gamma-delta T cells that affect the immunity of epithelial cells without affecting them. Accordingly, by performing fractionation using ethyl acetate on the ginseng leaf extract of the present invention and removing the ethyl acetate fraction to remove components soluble in ethyl acetate, using the purified fraction, IL-2, a factor involved in systemic immunity, Since there is no change in IL-13, which is an indicator of hypersensitivity immune response, only IL-13 is reduced, so it can be confirmed that there is an effect of improving hypersensitivity immune response while maintaining the body's defense mechanism.
상기와 같이 얻어지는 본 발명의 인삼잎 추출물의 분획 정제물은 과민성 면역 반응 개선을 위한 조성물의 유효성분으로 이용될 수 있다. 상기 과민성 면역 반응 개선용 조성물은 화장료 조성물일 수 있다.The fractionally purified product of the ginseng leaf extract of the present invention obtained as described above can be used as an active ingredient of a composition for improving hypersensitivity immune response. The composition for improving the hypersensitive immune response may be a cosmetic composition.
본 발명의 과민성 면역 반응 개선용 화장료 조성물은 상기 인삼잎 추출물에 물과 에틸아세테이트를 첨가하여 분획한 후 에틸아세테이트 분획물을 제거한 분획 정제물을 유효성분으로 포함하고, 상기 인삼잎 추출물의 분획 정제물을, 상기 화장료 조성물 총 100 중량%에 대하여 0.0001 내지 20 중량%, 또는 0.001 내지 15 중량%, 또는 0.01 내지 12 중량%, 또는 0.05 내지 10 중량%, 또는 0.1 내지 1 중량% 포함할 수 있다.The cosmetic composition for improving hypersensitivity immune response of the present invention contains, as an active ingredient, a purified fraction obtained by adding water and ethyl acetate to the ginseng leaf extract and then removing the ethyl acetate fraction, as an active ingredient. , 0.0001 to 20% by weight, or 0.001 to 15% by weight, or 0.01 to 12% by weight, or 0.05 to 10% by weight, or 0.1 to 1% by weight based on the total 100% by weight of the cosmetic composition.
본 발명에서 "과민성 면역 반응"은 식품 유발 과민 반응, 약물 유발 과민 반응, 광 조사에 의한 과민 반응, 화학물질 유발 과민 반응 등을 비제한적으로 포함한다. 상기 과민성 면역 반응의 '조절' 또는 '개선'은 상기 조성물이 투여되는 개체에서 과민성 면역 반응이 약화되거나 진정되는 것을 포함하여 이로써 파생되는 효과, 즉 과민성 면역 반응에 의해 유발되는 질환의 발병률이 저하되는 등의 효과를 의미할 수 있다.In the present invention, "hypersensitive immune response" includes, but is not limited to, food-induced hypersensitivity reaction, drug-induced hypersensitivity reaction, light irradiation-induced hypersensitivity reaction, chemical substance-induced hypersensitivity reaction, and the like. The 'regulation' or 'improvement' of the hypersensitive immune response includes the weakening or calming of the hypersensitive immune response in the subject to which the composition is administered, and the effect derived therefrom, that is, the incidence of diseases caused by the hypersensitive immune response is reduced. effects such as
본 발명의 화장료 조성물은 화장품 분야에서 통상적으로 사용되는 기제, 보조제 및 첨가제를 사용하여 액체 또는 고체 형태로 제조될 수 있다. 액체 또는 고체 형태의 화장품으로는, 예를 들면 이에 한정되지는 않으나 화장수, 크림제, 로션제, 입욕제 등의 형태를 포함할 수 있다.The cosmetic composition of the present invention may be prepared in liquid or solid form using bases, adjuvants and additives commonly used in the field of cosmetics. Cosmetics in liquid or solid form may include, but are not limited to, cosmetic products, creams, lotions, and bath products.
화장품 분야에서 통상적으로 사용되는 기제, 보조제 및 첨가제는 특별히 제한되지 않으며, 예를 들면 물, 알코올, 프로필렌글리콜, 스테아르산, 글리세롤, 세틸알코올, 유동 파라핀 등이 있다. Bases, adjuvants and additives commonly used in the field of cosmetics are not particularly limited, and examples thereof include water, alcohol, propylene glycol, stearic acid, glycerol, cetyl alcohol, and liquid paraffin.
본 발명의 조성물이 화장료 조성물로 제조되는 경우, 본 발명의 조성물은 상기 인삼잎 추출물의 분획 정제물뿐만 아니라, 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다.When the composition of the present invention is prepared as a cosmetic composition, the composition of the present invention may include components commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, as well as fractionated and purified ginseng leaf extracts. conventional adjuvants such as agents, vitamins, pigments and flavors, and carriers.
본 발명의 화장료 조성물은 본 기술분야에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이, 파우더, 헤어토닉, 헤어로션, 헤어크림, 헤어스프레이, 헤어무스, 헤어젤, 헤어컨디셔너, 헤어샴푸, 헤어 린스, 헤어팩, 헤어트리트먼트, 애완동물용 샴푸, 애완동물용 린스, 핸드크림, 손 세정제, 세제, 비누, 소독청결제, 물티슈, 마스크, 연고제, 패치 또는 필터 충진제의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, softening lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, hair tonic, hair lotion, hair cream, hair spray, hair Mousse, hair gel, hair conditioner, hair shampoo, hair conditioner, hair pack, hair treatment, pet shampoo, pet conditioner, hand cream, hand sanitizer, detergent, soap, disinfectant, wet wipes, mask, ointment, patch or as a formulation of a filter filler.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸카보네이트, 에틸아세테이트, 벤질알코올, 벤질벤조에이트, 프로필렌글리콜, 1,3-부틸렌글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkyl Amidobetaine, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used.
본 발명의 화장료 조성물은 단독 또는 중복 도포하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복 도포하여 사용할 수 있다. 또한 본 발명의 화장료 조성물은 통상적인 사용 방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention may be used alone or overlapping, or may be used overlapping with other cosmetic compositions other than the present invention. In addition, the cosmetic composition of the present invention can be used according to a conventional method of use, and the number of times of use can be varied according to the user's skin condition or taste.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클린징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징 크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, surfactant-containing cleansing or surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, removed, or washed with water. As specific examples, the soap is liquid soap, powder soap, solid soap, and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel, and a cleansing pack, and the surfactant-free cleansing formulation is a cleansing cream. , cleansing lotion, cleansing water and cleansing gel, but are not limited thereto.
본 발명의 다른 양태는 인삼잎 추출물에 에틸아세테이트와 물을 첨가하고 상기 에틸아세테이트 분획물을 제거하여 수득된 분획 정제물을 포함하는, 과민성 면역 반응 반응에 의해 유발되는 질환의 예방 또는 치료용 조성물을 제공한다. Another aspect of the present invention provides a composition for preventing or treating diseases caused by hypersensitivity immune response, comprising a purified fraction obtained by adding ethyl acetate and water to a ginseng leaf extract and removing the ethyl acetate fraction. do.
상기 본 발명의 과민성 면역 반응에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물은 상기 인삼잎 추출물에 물과 에틸아세테이트를 첨가하여 분획한 후 에틸아세테이트 분획물을 제거한 분획 정제물을 유효성분으로 포함하고, 상기 인삼잎 추출물의 분획 정제물을, 상기 약학적 조성물 총 100 중량%에 대하여 0.0001 내지 20 중량%, 또는 0.001 내지 15 중량%, 또는 0.01 내지 12 중량%, 또는 0.05 내지 10 중량%, 또는 0.1 내지 1 중량% 포함할 수 있다.The pharmaceutical composition for the prevention or treatment of diseases caused by hypersensitivity immune response of the present invention contains, as an active ingredient, a fractionated purified product obtained by adding water and ethyl acetate to the ginseng leaf extract and then fractionating and removing the ethyl acetate fraction. , 0.0001 to 20% by weight, or 0.001 to 15% by weight, or 0.01 to 12% by weight, or 0.05 to 10% by weight, or 0.1 to 1% by weight.
본 발명에서 "예방"은 상기 조성물에 의해서, 과민성 면역 반응에 의해 유발되는 질환을 억제 또는 지연시키는 모든 행위를 말하며, "치료"는 상기 조성물에 의해서, 과민성 면역 반응에 의해 유발되는 질환이 호전되거나 이롭게 변경되는 모든 행위를 말한다.In the present invention, "prevention" refers to any action that suppresses or delays a disease caused by an overactive immune response by the composition, and "treatment" means that a disease caused by an overactive immune response is improved by the composition or It refers to all actions that change in a beneficial way.
본 발명에서 "과민성 면역 반응에 의해 유발되는 질환"은 아토피성 피부염, 알레르기성 두드러기, 알레르기성 비염, 알레르기성 천식, 아낙팔락시스, 식품(우유, 계란, 땅콩, 콩, 밀, 해산물 등)에 의한 알레르기, 페니실린 알레르기, 자가면역 용혈성 빈혈, 굿파스처 증후군, 전신 홍반 루푸스, 혈청병, 아르투스 반응, 접촉성 피부염, 접촉성 아토피 피부염, 피부이식 거부반응, 자가면역성 심근염, 인슐린 의존형 당뇨병, 염증성 결절, 말초신경병증, 하시모토병, 염증성 장질환, 다발성경화증, 류마티스 관절염, 투베르쿨린 반응 등을 포함하고, 바람직하게는 아토피성 피부염, 알레르기성 두드러기, 알레르기성 비염, 알레르기성 천식, 아낙팔락시스, 식품(우유, 계란, 땅콩, 콩, 밀, 해산물 등)에 의한 알레르기, 페니실린 알레르기, 접촉성 피부염, 접촉성 아토피 피부염, 피부이식 거부반응, 자가면역성 심근염, 인슐린 의존형 당뇨병, 염증성 결절, 말초신경병증, 하시모토병, 염증성 장질환, 다발성경화증, 류마티스 관절염, 및 투베르쿨린 반응 등일 수 있으며, 특히 바람직하게는 접촉성 피부염, 접촉성 아토피 피부염, 피부이식 거부반응일 수 있으나, 이에 한정하지는 않는다.In the present invention, "diseases caused by hypersensitive immune response" include atopic dermatitis, allergic urticaria, allergic rhinitis, allergic asthma, anaphylaxis, food (milk, eggs, peanuts, soybeans, wheat, seafood, etc.) allergy, penicillin allergy, autoimmune hemolytic anemia, Goodpasture syndrome, systemic lupus erythematosus, serum sickness, Artus reaction, contact dermatitis, contact atopic dermatitis, skin graft rejection, autoimmune myocarditis, insulin-dependent diabetes mellitus, inflammatory nodule , peripheral neuropathy, Hashimoto's disease, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, tuberculin reaction, etc., preferably atopic dermatitis, allergic urticaria, allergic rhinitis, allergic asthma, anaphalaxis, food ( allergy to milk, egg, peanut, soybean, wheat, seafood, etc.), penicillin allergy, contact dermatitis, contact atopic dermatitis, skin graft rejection, autoimmune myocarditis, insulin-dependent diabetes mellitus, inflammatory nodule, peripheral neuropathy, Hashimoto disease, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and tuberculin reaction, and the like, and particularly preferably contact dermatitis, contact atopic dermatitis, and skin graft rejection, but are not limited thereto.
본 발명의 약학적 조성물은 상기 인삼잎 추출물의 분획 정제물 외에 본 발명이 목적으로 하는 효과를 손상시키지 않는 범위 내에서, 바람직하게는 상기 인삼잎 추출물의 분획 정제물의 효과에 상승 효과를 줄 수 있는 다른 성분 등을 추가로 함유할 수 있다. 예를 들어 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 또는 담체를 포함할 수 있다.The pharmaceutical composition of the present invention, in addition to the fractional purification of the ginseng leaf extract, can give a synergistic effect to the effect of the fractionally purified fraction of the ginseng leaf extract, preferably within a range that does not impair the desired effect of the present invention. It may further contain other components and the like. conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, or carriers.
상기 약학적 조성물은 상기 인삼잎 추출물의 분획 정제물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 상기 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition may contain at least one active ingredient exhibiting the same or similar function in addition to the fractionally purified product of the ginseng leaf extract. The composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively.
경구 투여를 위한 고형 제제에는 산제, 과립제, 정제, 캡슐제, 연질 캅셀제, 환 등이 포함된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills and the like. Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.
비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 멸균된 수용액, 액제, 비수성용제, 현탁제, 에멀젼, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학적 조성물을 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include powders, granules, tablets, capsules, sterilized aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc., and sterile injection preparations according to conventional methods, respectively. It can be formulated and used in the form of a cream, gel, patch, spray, ointment, warning, lotion, liniment, pasta, or cataplasma. , but is not limited thereto. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.
상기 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 보조제, 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법인 혼합, 과립화 또는 코팅 방법에 따라 제형화할 수 있다.The composition may further contain adjuvants such as preservatives, stabilizers, hydration agents or emulsification accelerators, salts and/or buffers for osmotic pressure control, and other therapeutically useful substances, which are conventional methods such as mixing, granulation or It can be formulated according to the coating method.
본 발명의 약학적 조성물은 과민성 면역 반응 개선을 목적으로 하는 개체이면 특별히 한정되지 않고, 어떠한 것이든 적용가능하다. 예를 들면, 본 발명의 약학적 조성물은 인간뿐만 아니라 원숭이, 개, 고양이, 토끼, 모르모트, 랫트, 마우스, 소, 양, 돼지, 염소 등과 같은 인간이 아닌 동물, 조류 및 어류 등 어느 것에 사용가능하다.The pharmaceutical composition of the present invention is not particularly limited as long as it is a subject for the purpose of improving the hypersensitive immune response, and any one is applicable. For example, the pharmaceutical composition of the present invention can be used not only for humans but also for non-human animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cows, sheep, pigs, goats, birds and fish. do.
상기 약학적 조성물의 투여 경로는 구강, 정맥내, 근육내, 동맥내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장이 포함되고, 예컨대 도포에 의한 국부투여(topical application) 방식으로 적용될 수 있다. 상기 비경구는 피하, 피내, 정맥내, 근육내, 병소내 주사 또는 주입기술을 포함한다. The route of administration of the pharmaceutical composition includes oral, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal, for example topical application by application method can be applied. The parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intralesional injection or infusion techniques.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여할 수 있다.The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount.
본 발명에서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 질병의 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 본 기술분야의 통상의 기술자에 의해 용이하게 결정될 수 있다.In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the subject, age, sex, type of disease, It may be determined according to the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of excretion, the duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be single or multiple administrations. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all of the above factors, and can be easily determined by a person skilled in the art.
상기 약학적 조성물의 투여량은 개체의 연령, 체중, 일반적인 건강, 성별, 투여시간, 투여 경로, 배출률, 약물 배합 및 특정 질환의 중증을 포함한 여러 요인에 따라 다양하게 변할 수 있다. The dose of the pharmaceutical composition may vary depending on various factors including age, body weight, general health, sex, administration time, route of administration, excretion rate, drug combination, and severity of a specific disease.
또한, 본 발명의 약학적 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다. 또한 상기 약학적 조성물은 성인 기준으로 0.001 내지 200㎎/㎏ 범위 내의 투여량으로 투여될 수 있고, 상기 약학적 조성물이 외용제인 경우에는 성인기준으로 1.0 내지 3.0㎖의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속하는 것이 좋으나, 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.In addition, the pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers. In addition, the pharmaceutical composition may be administered in a dosage within the range of 0.001 to 200 mg / kg on an adult basis, and when the pharmaceutical composition is an external agent, in an amount of 1.0 to 3.0 ml on an adult basis once a day to 5 times a day. It is recommended to apply once and continue for 1 month or longer, but the dosage is not intended to limit the scope of the present invention.
상기 약학적 조성물을 단위 용량 형태로 제형화하는 경우, 유효성분으로서 본 발명의 인삼잎 추출물의 분획 정제물은 g 당 약 0.1 내지 10㎎의 단위 용량으로 함유되는 것이 바람직하고, 성인 치료에 필요한 투여량은 투여의 빈도와 강도에 따라 하루에 약 1 내지 500㎎ 범위가 보통이나 이에 한정되는 것은 아니며, 일부 환자의 경우 더 높은 1일 투여량이 바람직할 수 있다.When the pharmaceutical composition is formulated in a unit dose form, it is preferable to contain the purified fraction of the ginseng leaf extract of the present invention as an active ingredient in a unit dose of about 0.1 to 10 mg per g, and the administration required for adult treatment The amount is usually in the range of about 1 to 500 mg per day, depending on the frequency and intensity of administration, but is not limited thereto, and higher daily dosages may be desirable for some patients.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by examples.
단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 내용이 하기 제조예, 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following examples are only for exemplifying the present invention, and the contents of the present invention are not limited by the following preparation examples, examples and experimental examples.
<제조예 1> <Production Example 1>
1-1. 인삼잎 물 추출물1-1. Ginseng Leaf Water Extract
인삼잎 0.5㎏에 정제수를 10배수 가하여 25℃에서 24시간 동안 1회 추출한 후 감압농축기를 이용하여 용매를 모두 제거하여 인삼잎 물 추출물을 제조하였다.Purified water was added 10 times to 0.5 kg of ginseng leaves, extracted once at 25° C. for 24 hours, and then all solvents were removed using a vacuum concentrator to prepare a water extract of ginseng leaves.
1-2. 인삼잎 에탄올 추출물1-2. Ginseng Leaf Ethanol Extract
인삼잎 0.5㎏에 70% 이상의 에탄올을 10배수 가하여 25℃에서 24시간 동안 1회 추출한 후 감압농축기를 이용하여 용매를 모두 제거하여 인삼잎 추출물을 제조하였다.A ginseng leaf extract was prepared by adding 10 times more 70% ethanol to 0.5 kg of ginseng leaves, extracting once at 25° C. for 24 hours, and then removing all solvents using a vacuum concentrator.
1-3. 인삼잎 추출물의 에틸아세테이트 분획 정제물1-3. Ethyl acetate fraction purified from ginseng leaf extract
상기 제조예 1-2의 인삼잎 에탄올 추출물에 정제수 5L를 넣고 용해시킨 후 에틸아세테이트 1.25L를 넣고 완전히 혼합한 후 분획 깔대기에 넣은 후 상온에서 1시간 동안 분리시켰다. 분리된 층의 하층부(정제수층)만을 회수한 후 감압농축하여 고형분으로서 인삼잎 추출물의 에틸아세테이트 분획 정제물을 제조하였다. After dissolving the ginseng leaf ethanol extract of Preparation Example 1-2 in 5L of purified water, 1.25L of ethyl acetate was added, thoroughly mixed, and then placed in a separatory funnel and separated at room temperature for 1 hour. After recovering only the lower layer (purified water layer) of the separated layer, it was concentrated under reduced pressure to prepare a purified ethyl acetate fraction of the ginseng leaf extract as a solid.
1-4. 인삼잎 추출물의 에틸아세테이트 분획물1-4. Ethyl acetate fraction from ginseng leaf extract
상기 제조예 1-2의 인삼잎 에탄올 추출물에 정제수 5L를 넣고 용해시킨 후 에틸아세테이트 1.25L를 넣고 완전히 혼합한 후 분획 깔대기에 넣은 후 상온에서 1시간 동안 분리시켰다. 또한, 상기 분리된 층의 상층부(에틸아세테이트)를 회수한 후 감압농축하여 고형분으로서 인삼잎 추출물의 에틸아세테이트 분획물을 제조하였다. After dissolving the ginseng leaf ethanol extract of Preparation Example 1-2 in 5L of purified water, 1.25L of ethyl acetate was added, thoroughly mixed, and then placed in a separatory funnel and separated at room temperature for 1 hour. In addition, the upper part (ethyl acetate) of the separated layer was recovered and concentrated under reduced pressure to prepare an ethyl acetate fraction of the ginseng leaf extract as a solid content.
<실험예 1> 알파-베타 T 세포에 미치는 피부면역 조절 효능의 확인<Experimental Example 1> Confirmation of skin immune regulation effect on alpha-beta T cells
전신 림프절을 수확하여 RPMI 1640 배지에 희석시킨 후, 96-웰 배양 플레이트에 1×105 세포/웰 용량으로 분주하였다. 이 세포에 콘카나발린 A를 4 ㎍/㎖ 농도로 처리해 T 면역세포를 활성화시킨 후 제조예 1의 각 추출물, 분획물, 또는 분획 정제물을 첨가하여 37℃, 가습, 5% CO2 인큐베이터에서 배양하였다. 배양 시작 2일 후, 배양 상층액을 수확하여 마우스 IL-2 ELISA 레디-셋-고 키트(이바이오사이언스)를 이용하여 제조사의 설명서에 따라 ELISA(효소-연결된 면역흡착 분석)를 수행하여 수집된 배양 상층액 내 IL-2 사이토카인 농도를 측정하고 하기 계산식에 따라 상대적인 IL-2 생산율을 산출하였다.Whole body lymph nodes were harvested, diluted in RPMI 1640 medium, and dispensed into 96-well culture plates at a capacity of 1×10 5 cells/well. The cells were treated with concanavalin A at a concentration of 4 μg/ml to activate T immune cells, and then each extract, fraction, or fraction purified product of Preparation Example 1 was added and cultured in a 37° C., humidified, 5% CO 2 incubator. did Two days after the start of culture, the culture supernatant was harvested and collected by ELISA (Enzyme-Linked Immunosorbent Assay) using the Mouse IL-2 ELISA Ready-Set-Go Kit (eBioscience) according to the manufacturer's instructions. The IL-2 cytokine concentration in the culture supernatant was measured, and the relative IL-2 production rate was calculated according to the following formula.
% IL-2 생산율 = 100×(시험군의 IL-2 농도)/(대조군의 IL-2 농도)% IL-2 production rate = 100 × (IL-2 concentration of test group) / (IL-2 concentration of control group)
또한, MTT(3(4,5-디메틸티아졸-2-일)-2,5-디페닐테트라졸륨 브로마이드) 환원법을 수행하여 T 세포에 대한 독성을 확인하였다. 구체적으로 IL-2 사이토카인 농도를 측정하기 위해 상층액을 제거한 후 남아있는 T 세포에 MTT(2.5 ㎎/㎖)를 배지에 10배 희석시킨 희석액을 1㎖ 첨가한 후 37℃에서 4시간 동안 배양하였다. 배양이 완료된 후 배지를 제거하고, DMSO 0.5㎖를 첨가하여 상온에서 10분 동안 완전히 녹인 후 570nm 및 670nm에서 흡광도를 측정하여 하기 계산식에 따라 림프절 T 세포의 상대적 생존률을 측정하였다.In addition, toxicity to T cells was confirmed by performing MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction method. Specifically, to measure the IL-2 cytokine concentration, after removing the supernatant, 1 ml of a 10-fold dilution of MTT (2.5 mg/ml) in the medium was added to the remaining T cells, followed by incubation at 37°C for 4 hours. did After the culture was completed, the culture medium was removed, 0.5 ml of DMSO was added, and the mixture was completely dissolved at room temperature for 10 minutes, and then the absorbance was measured at 570 nm and 670 nm to measure the relative viability of lymph node T cells according to the following formula.
% 림프절 T 세포 생존률 = 100×(시험군의 A570-A670)/(대조군의 A570-A670)% lymph node T cell viability = 100×(A570-A670 in the test group)/(A570-A670 in the control group)
<실험예 2> 감마-델타 T 세포에 미치는 피부면역 조절 효능의 확인<Experimental Example 2> Confirmation of skin immune regulation effect on gamma-delta T cells
피부생검 표본을 2.4 U/㎖ 디스파제 II가 포함된 RPMI 배지에 넣어 4℃에서 하룻밤 동안 반응시킨 후 피부 표피 조직만을 진피로부터 분리해 낸 다음 0.3% 트립신-GNK 용액을 37℃에서 10분 동안 처리한 후 교반하였다. 수집된 표피 세포 현탁액을 히스토파크(Histopaque) 1083 용액을 이용하여 실온에서 400×g으로 30분 동안 구배 원심분리하여 T 세포를 농축하였다. 수집된 상피 세포를 10 U/㎖ 마우스 IL-13이 포함된 완전 배지에 재현탁하고 37℃, 5% CO2 배양기에서 하룻밤 동안 배양하였다. 다음 날 24-웰 세포 배양 플레이트에 고정시킨 10 ㎎/㎖ 항-마우스 CD3 mAb 및 100 U/㎖ IL-13과 함께 제조예 1의 각 추출물, 분획물, 또는 분획 정제물을 첨가하여 37℃, 가습, 5% CO2 인큐베이터에서 배양하였다. 배양 5일 후, 배양 상층액을 수집하고 마우스 IL-13 ELISA 레디-셋-고 키트(이바이오사이언스)를 이용하여 제조사의 설명서에 따라, ELISA를 수행하여 수집된 배양 상층액 내 IL-13 사이토카인 농도를 측정하고 하기 계산식에 따라 상대적인 IL-13 생산율을 산출하였다.The skin biopsy specimen was put in RPMI medium containing 2.4 U/ml dispase II and reacted overnight at 4°C. and then stirred. The collected epidermal cell suspension was enriched for T cells by gradient centrifugation at room temperature at 400 x g for 30 minutes using Histopaque 1083 solution. The collected epithelial cells were resuspended in complete medium containing 10 U/ml mouse IL-13 and cultured overnight in a 37°C, 5% CO 2 incubator. The next day, each extract, fraction, or fraction purified of Preparation Example 1 was added together with 10 mg/ml anti-mouse CD3 mAb and 100 U/ml IL-13 immobilized in a 24-well cell culture plate, and humidified at 37°C. , and cultured in a 5% CO 2 incubator. After 5 days of culture, the culture supernatant was collected and ELISA was performed using the mouse IL-13 ELISA Ready-Set-Go kit (eBioscience) according to the manufacturer's instructions, and IL-13 cytotoxicity in the collected culture supernatant was performed. Caine concentration was measured and relative IL-13 production rate was calculated according to the following formula.
% IL-13 생산율 = 100×(시험군의 IL-13 농도)/(대조군의 IL-13 농도)% IL-13 production rate = 100 × (IL-13 concentration of the test group) / (IL-13 concentration of the control group)
또한, 상기 배양 상층액을 수집하여 활성화된 T 세포의 생존률을 프로피디움 아이오딘화물(PI) 배제 방법을 수행하여 확인하였다. 세포를 1 ㎍/㎖ PI가 포함된 차가운 PBS에서 현탁시키고 BD FACSCalibur 유세포 분석기(BD 바이오사이언스)를 이용한 유세포 분석을 수행하여 전체 세포군에서 약하게 적색 형광 신호를 나타내는 생존 세포의 수를 측정하였다. 상기 결과를 셀 퀘스트 소프트웨어(BD 바이오사이언스)로 분석하고 하기 계산식에 따라 상피 T 세포의 상대적인 생존률을 산출하였다. In addition, the viability of T cells activated by collecting the culture supernatant was confirmed by performing a propidium iodide (PI) exclusion method. Cells were suspended in cold PBS containing 1 μg/ml PI and flow cytometric analysis using a BD FACSCalibur flow cytometer (BD Biosciences) was performed to determine the number of viable cells showing a weak red fluorescence signal in the total cell population. The results were analyzed with Cell Quest software (BD Biosciences) and the relative viability of epithelial T cells was calculated according to the following formula.
% 상피 T 세포 생존률 = 100×(시험군 내 생존 세포 수)/(대조군 내 생존 세포 수)% epithelial T cell viability = 100×(number of viable cells in test group)/(number of viable cells in control group)
상기 제조예 1의 각 추출물, 분획물, 또는 분획 정제물에 대해 림프절 T 세포의 생존율(a), 상피 T 세포의 생존율(b), IL-2 생산율(c) 및 IL-13 생산율(d)을 측정한 결과를 각각 도 1 내지 도 4에 나타낸다. For each extract, fraction, or fraction purified product of Preparation Example 1, the survival rate of lymph node T cells (a), the survival rate of epithelial T cells (b), the production rate of IL-2 (c) and the production rate of IL-13 (d) The measured results are shown in FIGS. 1 to 4, respectively.
상기 결과로부터, 본 발명에 따른 제조예 1-3의 인삼잎 추출물의 에틸아세테이트 분획 정제물의 경우 림프절과 상피에 존재하는 T 세포에 독성을 나타내지 않으며, 과민성 면역 반응을 일으키는 인자인 IL-13의 생성을 감소시키지만 중추 면역에 관련된 IL-2에는 영향을 끼치지 않는 것을 확인할 수 있다 (도 3). From the above results, in the case of the purified ethyl acetate fraction of the ginseng leaf extract of Preparation Example 1-3 according to the present invention, it is not toxic to T cells present in lymph nodes and epithelium, and production of IL-13, a factor that causes hypersensitivity immune response However, it can be confirmed that IL-2 related to central immunity is not affected (FIG. 3).
반면, 제조예 1-2의 인삼잎 에탄올 추출물의 경우에는 과민성 면역 반응을 일으키는 인자인 IL-13의 생성을 감소시키지만, 중추 면역에 관련된 림프절 내 T 세포에 고농도에서 독성을 보이며 IL-2의 생성량을 크게 증가시킨다 (도 2).On the other hand, in the case of the ginseng leaf ethanol extract of Preparation Example 1-2, the production of IL-13, which is a factor that causes hypersensitivity immune response, is reduced, but it is toxic to T cells in the lymph nodes related to central immunity at high concentrations, and the amount of IL-2 produced greatly increase (Fig. 2).
한편, 제조예 1-1의 인삼잎 물 추출물은 림프절 T 세포에 대한 독성 및 IL-2의 생성에는 에탄올 추출물과 유사한 경향을 보이나 결정적으로 IL-13의 생성에는 영향이 없는 것으로 나타났다 (도 1).On the other hand, the ginseng leaf water extract of Preparation Example 1-1 showed a similar tendency to the ethanol extract in toxicity to lymph node T cells and IL-2 production, but decisively showed no effect on IL-13 production (FIG. 1) .
또한, 제조예 1-4의 인삼잎 추출물의 에틸아세테이트 분획물의 경우 다른 분획과 달리 림프절 및 상피 T 세포에 대한 높은 세포 독성을 보이며, 이로 인하여 IL-2, IL-13의 생성이 억제되는 것을 확인할 수 있다 (도 4). In addition, in the case of the ethyl acetate fraction of the ginseng leaf extract of Preparation Examples 1-4, unlike other fractions, it showed high cytotoxicity to lymph node and epithelial T cells, and it was confirmed that the production of IL-2 and IL-13 was inhibited. can (Fig. 4).
따라서, 제조예 1-2의 추출물과, 제조예 1-3의 분획 정제물의 경우 IL-13의 생성을 억제하는 효과가 우수하며, 특히 제조예 1-3의 경우 림프절에서 일어나는 중추 면역에는 영향을 미치지 않으면서, 상피조직에서 일어나는 과민성 면역 반응을 개선하거나 과민성 면역 반응에 의해 유발되는 질환을 예방하거나 치료하는 데 활용할 수 있을 것으로 예상된다. Therefore, in the case of the extract of Preparation Example 1-2 and the purified fraction of Preparation Example 1-3, the effect of inhibiting the production of IL-13 is excellent, and in the case of Preparation Example 1-3, in particular, the central immunity occurring in the lymph node is affected. It is expected that it can be used to improve the hypersensitive immune response occurring in epithelial tissues or to prevent or treat diseases caused by the hypersensitive immune response.
<제조예 2> 화장료 조성물의 제조<Preparation Example 2> Preparation of cosmetic composition
<2-1> 에센스의 제조<2-1> Preparation of essence
제조예 1-3의 인삼잎 추출물의 에틸아세테이트 분획 정제물을 이용하여 하기 표 1에 기재된 함량(중량부)에 따라 에센스를 제조하였다.Using the purified ethyl acetate fraction of the ginseng leaf extract of Preparation Example 1-3, an essence was prepared according to the contents (parts by weight) shown in Table 1 below.
<2-2> 유연화장수의 제조<2-2> Preparation of softening lotion
제조예 1-3의 인삼잎 추출물의 에틸아세테이트 분획 정제물을 유효성분으로 함유하는 유연화장수는 하기 표 2와 같이 제조하였다.Softening lotion containing the purified ethyl acetate fraction of the ginseng leaf extract of Preparation Example 1-3 as an active ingredient was prepared as shown in Table 2 below.
<2-3> 영양 크림의 제조<2-3> Manufacture of nutrient cream
제조예 1-3의 인삼잎 추출물의 에틸아세테이트 분획 정제물을 유효성분으로 함유하는 영양크림은 하기 표 3의 조성과 같이 제조하였다. A nourishing cream containing the purified ethyl acetate fraction of the ginseng leaf extract of Preparation Example 1-3 as an active ingredient was prepared according to the composition shown in Table 3 below.
<2-4> 로션의 제조<2-4> Manufacture of Lotion
제조예 1-3의 인삼잎 추출물의 에틸아세테이트 분획 정제물을 유효성분으로 함유한 로션을 하기 표 4의 조성과 같이 제조하였다. A lotion containing the purified ethyl acetate fraction of the ginseng leaf extract of Preparation Example 1-3 as an active ingredient was prepared according to the composition shown in Table 4 below.
Claims (7)
상기 인삼잎 추출물은 에탄올을 용매로 하여 추출한 것인 조성물.The method of claim 1,
The ginseng leaf extract is a composition that is extracted with ethanol as a solvent.
상기 과민성 면역 반응은 식품 유발 과민 반응, 약물 유발 과민 반응, 광 조사에 의한 과민 반응, 또는 화학물질 유발 과민 반응을 포함하는 조성물. The method of claim 1,
The hypersensitivity immune response is a composition comprising a food-induced hypersensitivity reaction, a drug-induced hypersensitivity reaction, a hypersensitivity reaction by light irradiation, or a chemical-induced hypersensitivity reaction.
상기 과민성 면역 반응의 개선용 조성물은 화장료 조성물인 조성물.The method of claim 1,
The composition for improving the hypersensitivity immune response is a cosmetic composition.
상기 과민성 면역 반응에 의해 유발되는 질환은 아토피성 피부염, 알레르기성 두드러기, 알레르기성 비염, 알레르기성 천식, 아낙팔락시스, 식품(우유, 계란, 땅콩, 콩, 밀, 해산물 등)에 의한 알레르기, 페니실린 알레르기, 접촉성 피부염, 접촉성 아토피 피부염, 피부이식 거부반응, 자가면역성 심근염, 인슐린 의존형 당뇨병, 염증성 결절, 말초신경병증, 하시모토병, 염증성 장질환, 다발성경화증, 류마티스 관절염, 및 투베르쿨린 반응으로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 조성물.The method of claim 5,
Diseases caused by the hypersensitivity immune response include atopic dermatitis, allergic urticaria, allergic rhinitis, allergic asthma, anaphylaxis, allergy to food (milk, egg, peanut, soybean, wheat, seafood, etc.), penicillin Allergy, contact dermatitis, contact atopic dermatitis, skin graft rejection, autoimmune myocarditis, insulin dependent diabetes mellitus, inflammatory nodule, peripheral neuropathy, Hashimoto's disease, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and tuberculin reaction A composition comprising at least one member selected from
상기 과민성 면역 반응에 의해 유발되는 질환은 접촉성 피부염, 접촉성 아토피 피부염, 또는 피부이식 거부반응인 조성물.The method of claim 5,
Diseases caused by the hypersensitive immune response are contact dermatitis, contact atopic dermatitis, or skin graft rejection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210190651A KR20230100953A (en) | 2021-12-29 | 2021-12-29 | Composition For Improving Hypersensitive Immune Response |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210190651A KR20230100953A (en) | 2021-12-29 | 2021-12-29 | Composition For Improving Hypersensitive Immune Response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230100953A true KR20230100953A (en) | 2023-07-06 |
Family
ID=87185782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210190651A KR20230100953A (en) | 2021-12-29 | 2021-12-29 | Composition For Improving Hypersensitive Immune Response |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230100953A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101624640B1 (en) | 2013-09-12 | 2016-05-27 | 대한민국 | External skin preparation comprising ginsenoside F5 |
-
2021
- 2021-12-29 KR KR1020210190651A patent/KR20230100953A/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101624640B1 (en) | 2013-09-12 | 2016-05-27 | 대한민국 | External skin preparation comprising ginsenoside F5 |
Non-Patent Citations (3)
| Title |
|---|
| Circadian Gene Clock Regulates Psoriasis-Like Skin Inflammation in Mice. J Invest Dermatol. 2015 Dec;135(12):3001-3008. |
| Willoughby DA, Human arthritis applied to animal models, Towards a better therapy. Ann Rheum Dis 34: 471-478. 1975 |
| γδ T cells amplify Blomia tropicalis-induced allergic airway disease. Allergy. 2019 Feb;74(2):395-398. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101116852B1 (en) | Composition comprising an extract of Magnolia officinalis Rehd. et Wils. or 4-O-methylhonokiol isolated therefrom having anti-inflammatory, anti-allergy and anti-wrinkle activity | |
| EP3017822B1 (en) | Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof | |
| RU2423139C2 (en) | COMPOSITION CONTAINING Actinidia AND METHODS OF THEIR APPLICATION | |
| KR101221617B1 (en) | Anti-inflammatory agent containing stauntonia hexaphyllafruit leaf extract | |
| KR101367423B1 (en) | Pharmaceutical composition and cosmetic compostion for improving skin condition and preparation method thereof | |
| KR100999870B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata Thub and Ulmus davidana var.Japonica as an active ingredient | |
| JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
| KR101538743B1 (en) | Composition for Preventing, Improving or Treating of Ｔｈ1-mediated Immune Disease or Ｔｈ2-mediated Immune Disease Comprising Extracts from Saussurea lappa Clarke and Biota orientalis (L.) Endl. as an Active Ingredients | |
| KR101167589B1 (en) | Anti-inflammatory agent containing stauntonia hexaphylla fruit extract | |
| KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient | |
| KR20230100953A (en) | Composition For Improving Hypersensitive Immune Response | |
| KR102547208B1 (en) | A Composition For Enhancing Skin Immunity Comprising Column-purified Fraction Of Ginseng Extract | |
| KR20230012749A (en) | Composition For Improving Hypersensitive Immune Response | |
| KR102209969B1 (en) | Composition comprising Fritillariae Thunbergii Bulbs extract for preventing or treating atopic dermatitis | |
| KR101702621B1 (en) | Anti-inflammatory agent containing phlox subulata extract | |
| KR102272637B1 (en) | Anti-inflammatory composition comprising Prunus pendula for. ascendens (Makino) Ohwi | |
| KR102034436B1 (en) | Composition For Treating And Preventing Atopic Dermatitis Comprising Ternstroemia kwangtungensis Merr. Extracts | |
| KR20130074807A (en) | Cosmetics having muskrat musk | |
| JP2022006397A (en) | Barrier function enhancer | |
| KR101138962B1 (en) | A pharmaceutical composition for preventing or treating an allergic dermatologic disease | |
| JP2010202569A (en) | Antiallergic and anti-inflammatory composition | |
| KR20130032995A (en) | Anti inflammatory composition comprising tamarindus indica extract as effective composition | |
| KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient | |
| KR102198355B1 (en) | Pharmaceutical composition comprising Cymbidium extracts for preventing or treating allergic diseases or contact | |
| KR20140114709A (en) | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |